ArticleFrontiers in pharmacology2025

Rituximab in PR3-ANCA positive patients with moderately to severely active ulcerative colitis: a multicenter real-world pilot study.

Qi Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.